a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC Study

N/AActive Not RecruitingNCT06472635

Zhejiang University95 enrolled

Overview

Research Purpose 1: To evaluate the therapeutic efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the real-world setting. Research Purpose 2: To analyze the influencing factors of the therapeutic effect of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the real-world setting. Research Purpose 3: To understand the treatment patterns of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced ESCC in the

Study Type

OBSERVATIONAL

Enrollment

Conditions

The Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: Age ≥ 18 years (including 18 years old); ECOG 0 or 1; Patients with esophageal squamous cell carcinoma judged to be resectable (including initially non-resectable) by the researcher Received esophageal radical surgery and neoadjuvant immune chemotherapy before surgery Clinical staging belongs to: T1b-4NanyM0; Exclusion Criteria: Patients without complete medical information; Received other anti-tumor treatment before surgery; Received radiotherapy treatment; Judged by the researcher, have other conditions unsuitable for participating in this clinical study. Hide hide Contacts/Locations

Outcomes

Primary Outcomes

Pathological Complete Response (pCR)

pCR is defined as the ratio of residual viable tumor cells being 0 in the primary tumor and sampled lymph nodes.

Time frame: 12 months

Secondary Outcomes

Resection Rate

R0 resection refers to the complete removal of the tumor, with negative microscopic margins, indicating no residual tumor; no cancer cells are found on the cutting line under pathological examination.